Indaptus Therapeutics, Inc.
INDP
$0.4649
-$0.0151-3.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.69M | 1.68M | 2.39M | 2.35M | 2.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.17M | 3.14M | 4.11M | 3.94M | 4.18M |
| Operating Income | -4.17M | -3.14M | -4.11M | -3.94M | -4.18M |
| Income Before Tax | -4.13M | -3.07M | -4.02M | -3.81M | -4.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.13M | -3.07M | -4.02M | -3.81M | -4.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.13M | -3.07M | -4.02M | -3.81M | -4.00M |
| EBIT | -4.17M | -3.14M | -4.11M | -3.94M | -4.18M |
| EBITDA | -4.17M | -3.14M | -4.11M | -3.94M | -4.18M |
| EPS Basic | -0.38 | -0.32 | -0.47 | -0.45 | -0.48 |
| Normalized Basic EPS | -0.24 | -0.20 | -0.29 | -0.28 | -0.30 |
| EPS Diluted | -0.38 | -0.32 | -0.47 | -0.45 | -0.48 |
| Normalized Diluted EPS | -0.24 | -0.20 | -0.29 | -0.28 | -0.30 |
| Average Basic Shares Outstanding | 10.93M | 9.51M | 8.54M | 8.44M | 8.40M |
| Average Diluted Shares Outstanding | 10.93M | 9.51M | 8.54M | 8.44M | 8.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |